Nanomedicine for pancreatitis therapy: mechanism-guided design and translational challenges

Pancreatitis presents a formidable clinical challenge as a therapeutically underserved inflammatory disorder, where acute pancreatitis relies predominantly on supportive care and chronic pancreatitis lacks approved disease-modifying, anti fibrotic pharmacotherapies. Although nanomedicine holds immense promise for site specific intervention, conventional design paradigms leveraging tumor mimicking enhanced permeability and retention (EPR) effects or non-specific inflammation targeting fundamentally fail in the structurally distinct, enzyme rich microenvironment of the inflamed pancreas. This Review establishes a necessary paradigm shift, arguing that pancreatitis nanomedicines must transcend mere material novelty to be rationally engineered based on disease stage specific pathobiology. We systematically map critical biological nodes, including acinar cell calcium overload, premature digestive enzyme activation, mitochondrial dysfunction, innate immune amplification, endothelial leakage, and pancreatic stellate cell fibrogenesis, onto controllable nanoscale design variables, such as size, morphology, surface chemistry, mechanical stiffness, degradability, catalytic kinetics, and biomimetic identity. Furthermore, we dissect the unique physiological delivery barriers obstructing pancreatic transport, emphasizing tissue edema, elevated interstitial fluid pressure, fibrotic matrix remodeling, and enzyme mediated nano-bio interface remodeling. Leading polymeric, lipid, organosilica, catalytic nanozyme, and biomimetic nanoplatforms are critically evaluated regarding target engagement, translational pharmacodynamic readouts, therapeutic windows, safety, clearance pathways, and scalability. Finally, we outline a rigorous translational blueprint, tackling key hurdles including cell-resolved biodistribution, human plasma corona dynamics, proteolytic stability, quantitative pharmacokinetic/pharmacodynamic (PK/PD) relationships, potency assays, chemistry, manufacturing, and control (CMC), and safe-by-design strategies. By seamlessly coupling material identity with pancreatic pathobiology and clinically meaningful endpoints, this conceptual framework seeks to accelerate the transition of pancreatitis nanomedicine from empirical delivery systems to mechanism-guided translational pharmacology.